These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 1996743)

  • 21. Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
    da Costa-Rocha IA; Machado KLLL; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; de Lima SMB; Miranda EH; Trindade GF; Casagrande TZ; Miyamoto ST; Deotti SC; Barbosa RVR; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Valim V; Martins-Filho OA
    Sci Rep; 2021 May; 11(1):10431. PubMed ID: 34001945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine.
    Kollaritsch H; Que JU; Kunz C; Wiedermann G; Herzog C; Cryz SJ
    J Infect Dis; 1997 Apr; 175(4):871-5. PubMed ID: 9086143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Yellow fever outbreak in Ipetu-Ijesa: response after mass vaccination.
    Adu FD; Adeniji JA; Tomori O; Adelasoye A
    Rev Roum Virol; 1993; 44(1-2):3-7. PubMed ID: 8043476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
    Collaborative Group for Studies with Yellow Fever Vaccine
    Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies.
    Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Costa-Pereira C; Yamamura AY; Lima SMB; Simões M; Campos FMF; de Castro Zacche Tonini A; Lemos EM; Brum RC; de Noronha TG; Freire MS; Maia MLS; Camacho LAB; Rios M; Chancey C; Romano A; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    J Immunol Methods; 2017 Sep; 448():9-20. PubMed ID: 28514646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Use of stabilized yellow fever vaccine 17D at the time of the yellow fever epidemic in Burkina Faso in 1983].
    Saluzzo JF; Some L; Baudon D; Girault G; Lhuillier M; Kambire PA; Roux JF; Digoutte JP
    Bull Soc Pathol Exot Filiales; 1985; 78(4):536-40. PubMed ID: 4075474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures.
    Pereira RC; Silva AN; Souza MC; Silva MV; Neves PP; Silva AA; Matos DD; Herrera MA; Yamamura AM; Freire MS; Gaspar LP; Caride E
    Vaccine; 2015 Aug; 33(35):4261-8. PubMed ID: 25862300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A clinical study of stabilized 17D strain live attenuated yellow fever vaccine.
    Moss-Blundell AJ; Bernstein S; Shepherd WM; Langford DT; Ferris R; Kelly A
    J Biol Stand; 1981 Oct; 9(4):445-52. PubMed ID: 7320025
    [No Abstract]   [Full Text] [Related]  

  • 31. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine.
    Pappaioanou M; Fishbein DB; Dreesen DW; Schwartz IK; Campbell GH; Sumner JW; Patchen LC; Brown WJ
    N Engl J Med; 1986 Jan; 314(5):280-4. PubMed ID: 3510393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.
    Wieten RW; Goorhuis A; Jonker EFF; de Bree GJ; de Visser AW; van Genderen PJJ; Remmerswaal EBM; Ten Berge IJM; Visser LG; Grobusch MP; van Leeuwen EMM
    J Infect; 2016 Jun; 72(6):713-722. PubMed ID: 27017899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
    Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
    Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles.
    Goujon C; Gougeon ML; Tondeur L; Poirier B; Seffer V; Desprès P; Consigny PH; Vray M;
    Vaccine; 2017 Oct; 35(45):6166-6171. PubMed ID: 28958813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Arboviruses and lemurs in Madagascar: experimental infection of Lemur fulvus with attenuated strains of yellow fever virus].
    Rodhain F
    Bull Soc Pathol Exot Filiales; 1984; 77(3):255-62. PubMed ID: 6488418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Protection After Fractional-Dose Yellow Fever Vaccination: Follow-up Study of a Randomized, Controlled, Noninferiority Trial.
    Roukens AHE; van Halem K; de Visser AW; Visser LG
    Ann Intern Med; 2018 Dec; 169(11):761-765. PubMed ID: 30476963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
    Barrett AD; Teuwen DE
    Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The early cellular signatures of protective immunity induced by live viral vaccination.
    Kohler S; Bethke N; Böthe M; Sommerick S; Frentsch M; Romagnani C; Niedrig M; Thiel A
    Eur J Immunol; 2012 Sep; 42(9):2363-73. PubMed ID: 22733156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance assessment and validation of a plaque reduction neutralization test (PRNT) in support to yellow fever diagnostic and vaccine clinical trials.
    Dia M; Bob NS; Talla C; Dupressoir A; Escadafal C; Thiam MS; Diallo A; Ndiaye O; Heraud JM; Faye O; Sall AA; Faye O; Fall G
    J Med Virol; 2023 Apr; 95(4):e28700. PubMed ID: 36951314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
    Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
    J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.